Australia - engelsk - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; colloidal anhydrous silica; magnesium stearate - women:moderately severe to severe signs of androgenization. moderately severe/severe forms of hirsutism. moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe androgenic alopecia).moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenization.cyproterone acetate inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused either by increased production of androgens or a particular sensitivity to these hormones hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment.if cyprostat 50mg is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of childbearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular menstruation men:reduction o

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; maize starch - inoperable prostatic carcinoma. because of its anti-androgenic effect cyprostat is indicated for the treatment of inoperable prostatic carcinoma in patients who have failed primary hormonal manipulation or who are at risk from cardiovascular disease and/or intolerant of oestrogen therapy. indications as at 18 may 2005 : inoperable prostatic carcinoma. * to suppress flare with initial lhrh analogues therapy. * in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred. * in the treatment of hot flushes in pateinets treated with lhrh analogues or who have had orchiectomy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate -

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - cyproterone acetate - oral tablet - 50mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - cyproterone acetate - oral tablet - 100mg

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

schering (nz) limited - cyproterone acetate 100mg - tablet - 100 mg - active: cyproterone acetate 100mg excipient: lactose monohydrate magnesium stearate maize starch povidone

Malta - engelsk - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - cyproterone acetate - tablet - cyproterone acetate 50 mg - sex hormones and modulators of the genital system

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

stragen uk ltd - cyproterone acetate - oral tablet - 50mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - cyproterone acetate - oral tablet - 100mg